ArticleEClinicalMedicine2025
Sertraline to reduce recidivism in impulsive violent offenders (ReINVEST): a randomised double blind clinical trial.
Article in EClinicalMedicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- "It Was Like They'd Lit a Fuse": A Mixed-Methods Investigation Into Rage.Aggressive behavior · 2026Article
- Structured psychiatric care and psychosocial support during placebo participation: association with violent and domestic-violence offending in the ReINVEST trial.Frontiers in psychiatry · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Biological studies suggest serotonin modulation via selective serotonin reuptake inhibitors (SSRIs) might reduce impulsive violence, however, robust evidence in offender populations is limited. We aimed to determine whether sertraline reduces violent reoffending compared with placebo in highly impulsive men with recurrent violent offending. Methods: We conducted a double-blind, placebo-controlled, randomised clinical trial in community settings in New South Wales, Australia. Eligible participants were men aged 18 years or older with ≥2 prior violent convictions and a Barratt Impulsiveness Scale score ≥70. Following a 4-week single-blind active run-in phase with sertraline, participants were randomly assigned (1:1, minimization stratified by key factors) to receive oral sertraline (100 mg daily) or matching placebo for 12 months. The primary outcome was the first convicted violent offence within 12 months, assessed via linkage to the state Reoffending Database. The primary analysis followed the intention-to-treat principle. The trial is registered with ANZCTR (ACTRN12613000442707) and is closed to new participants. Findings: Between October 28, 2013, and July 13, 2021, 630 eligible men were randomly assigned: 319 to sertraline and 311 to placebo. By 12 months, only 204 participants remained engaged with the study. All participants were included in the primary analysis. A primary outcome event (violent offence within 12 months) occurred in 72 (22.6%) of 319 participants assigned sertraline and 70 (22.5%) of 311 assigned placebo (Relative Risk 1.00, 95% CI 0.75-1.34; p = 0.99). Serious adverse events occurred in 22 (6.9%) participants receiving sertraline and 29 (9.3%) receiving placebo. Interpretation: Sertraline did not significantly reduce the risk of violent reoffending compared with placebo. Post-hoc analyses suggested a possible selective effect on domestic violence offending. Funding: Initial funding for the ReINVEST trial was provided from an Australian National Health and Medical Research Council partnership grant No. 533559. From 2018, subsequent funding was provided by the NSW Department of Communities and Justice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.